Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Bionomics Ltd ADR
BNOXCurrent price
0.38 USD
+0.065 USD (+20.56%)
Last closed
0.28 USD
Company
www.bionomics.com.au
ISIN
US09063M2052
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
3 410 386 USD
Yield for 12 month
-84.74 %
1Y
3Y
5Y
10Y
15Y
BNOX
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia. Address: 200 Greenhill Road, Eastwood, SA, Australia, 5063
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6 USDP/E ratio
–Dividend Yield
–Current Year
+20 000 USD
Last Year
+432 666 USD
Current Quarter
+98 936 USD
Last Quarter
–
Current Year
-434 449 USD
Last Year
-12 630 654 USD
Current Quarter
-5 169 436 USD
Last Quarter
-436 348 USD
Key Figures BNOX
1 year
3 years
5 years
10 years
EBITDA
-17 351 144 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-39.58 %
PEG Ratio
–
Return On Equity TTM
-78.44 %
Wall Street Target Price
6 USD
Revenue TTM
661 980 USD
Book Value
1.32 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
9.3 %
Dividend Yield
–
Gross Profit TTM
-18 963 665 USD
Earnings per share
-1.8 USD
Diluted Eps TTM
-1.8 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics BNOX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BNOX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation BNOX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
62.941
Price Sales TTM
386.7211
Enterprise Value EBITDA
-0.0591
Price Book MRQ
0.195
Financials BNOX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators BNOX
For 52 weeks
0.18 USD
2.84 USD
50 Day MA
0.46 USD
Shares Short Prior Month
72 985
200 Day MA
0.79 USD
Short Ratio
0.05
Shares Short
13 778
Short Percent
0.09 %
BeatStart